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CHAPTER 1 : INTRODUCTION
1.1 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
Human immunodeficiency virus type 1 (HIV-1) is a lentivirus retrovirus that utilizes CD4+
T cells to replicate. As a result of this phenomena, CD4+ T cells no longer help with immunity;
this leads to immune system failure and increased susceptibility to infections [1]. At this stage, the
body cannot defend itself from foreign pathogens and succumbs to a HIV-1 related death [2]. Once
the number of CD4+ cells drop below a certain quantity, the HIV-1 positive status will evolve into
AIDS (Acquired Immune Deficiency Syndrome)[3].
HIV-1 can be acquired from an infected person by unprotected sexual intercourse, during
birth, or by a blood transfusion [4–6]. The transition to AIDS can take up to 15 years. The unique
genome and structure of the virus makes it one of the greatest current threats to human health [1,
3, 4].
1.2 HIV-1 EPIDEMIOLOGY
Since the discovery of AIDS in 1981, there has been a rapid decrease in the number of
infections in developed countries but in less developed countries there are still millions of new
infections every year (Fig. 1-1). In 1983, it was determined that HIV-1 was the instrumental agent
of AIDS [1, 7]. As of 2013, there were about 35.0 million people reported to be living with HIV1 internationally with 3.2 million being children under the age of 15, who reside mostly in low- to
middle- income countries. In 2013, 71% of the 2.1 million newly infected patients resided in SubSaharan Africa [8].
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Figure 1-1: An International Outlook on the HIV-1 Epidemic. According to the World Health
Organization, as of 2013, 35.0 million are infected with HIV-1, most of whom reside in SubSaharan Afric (Adapted from http://www.unaids.org/).
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1.3 HIV-1 GENOME
The HIV-1 genome has genes that code for several structural proteins that are common to
all the retroviruses; however, it also has over lapping and open reading frames for accessory
regulatory proteins which make the HIV-1 genome unique [9].
The genes of the HIV-1 genome that code for structural proteins are the gag, pol, and env
proteins (Fig. 1-2). The gag gene encodes the capsid proteins. The gag precursor encodes four viral
structural proteins – matrix (p17), capsid (p24), nucleocapsid (p7) and p6 – which are processed
by the mature viral protease. The gag- pol gene encodes three viral replicating proteins Integrase
(IN), Protease (PR), and Reverse Transcriptase (RT). The env gene encodes the surface
lipoproteins gp120 and gp41 [9, 10].
The essential regulatory elements of the HIV-1 genome are the tat and rev genes (Fig 1-2).
The tat gene regulates the reverse transcription of the viral RNA. This gene is responsible for
efficient synthesis of viral mRNAs and the regulation of the release of virions from infected cells.
The rev gene stimulates the production of HIV-1 proteins and suppresses the expression of HIV-1
regulatory genes [9].
The accessory regulatory genes are the nef, vif, vpr, and vpu genes (Fig. 1-2). The nef gene
encodes a protein that is located in the cell’s cytoplasm that retards HIV-1 replication. The vif gene
increases infectivity of HIV-1 particles and encourages the cell to degrade APOBEC3G (host cell
protein that acts as an innate antiviral agent). The vpr gene accelerates the production of HIV-1
proteins and the vpu gene helps with the assembly of new virus particles, helps them to bud from
the host cells and enhances the degradation of CD4+ proteins[9–12].
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Figure 1-2: The HIV-1 Genome. The HIV-1 genome consist of genes that encode structural and
replication proteins: gag( lime), pol ( light blue), and env ( orange) and regulatory proteins: vif
(pink), tat(yellow), rev ( purple), vpu (red), vpr (gray) and nef (green).
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1.4 HIV-1 LIFE CYCLE
HIV-1 has a similar structure as many of the retroviruses. The outer coat is around 120 nm
in diameter, roughly spherical and is composed of a lipid bilayer; this is known as the viral
envelope (Fig 1-3). Embedded throughout the viral envelope are proteins from the host cell and
72 copies of the HIV-1 surface envelope proteins called Env (Fig 1-3). Env spikes through the
surface of the viral envelope and consist of three glycoproteins and one hundred and twenty caps
that are anchored by stems. Beneath the viral envelope lies an HIV-1 protein called p17 or the
matrix. Past the matrix is the capsid formed by p24 proteins. Inside the capsid are non-covalently
linked positive single stranded RNA strands and the replication enzymes RT and IN (Fig.1- 3)[13,
14].
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Figure 1-3: The structure of HIV-1. HIV-1 consists of a spherical lipid membrane that encloses
a capsid which encloses its genetic information and replication proteins. On the surface of the
protein, there are docking glycoproteins that are required for docking and fusion into lymphocytes.
(Adapted from www.NIAID.gov).
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The HIV-1 life cycle has multiple steps that make it a highly infective provirus. First, a
free HIV-1 particle interacts with the surface of a CD4+ lymphocyte. The viral glycoproteins (g120
proteins) on the surface of the retrovirus bind to the CD4+ receptor and co-receptor on the surface
of the host cell. Once bound, the membranes fuse together forming an opening. The virus releases
a capsid containing two positive sense viral RNA strands, viral enzymes and viral core proteins
into the cytoplasm of the host cell (Fig.1- 3 and 1-4). The capsid core proteins are degraded, and
its contents are released into the cytoplasm. Reverse transcriptase takes the viral RNA strands and
reverse transcribes them into viral DNA in the cytoplasm of the host cell (Fig. 1-4). Integrase
integrates the viral DNA into the DNA of the infected cell by two mechanisms: 3’ processing and
stand transfer.
Once the infected cell is activated, the proviral DNA is transcribed into viral mRNA. The
viral mRNA leaves the nucleus and enters the cytoplasm where a new virus is being synthesized.
Some of the mRNA is translated into a polypeptide chain by a ribosome on the surface of the rough
endoplasmic reticulum. The remaining viral proteins are assembled on the surface of the infected
cell’s membrane. Once this occurs, two mRNA strands and the polyprotein chain are aligned on
the opposite side of the membrane of the glycoproteins on the surface of the infected cell. From
here, the new viral particle buds out the infected cell. Inside this new particle, protease cleaves
itself from this long polyprotein and it begins to cleave the remainder of the chain, forming the
matrix, the capsid, RT and IN establishing a mature virion (Fig. 1- 4) (review in ref. [15]).
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Figure 1-4: HIV-1 replication cycle. HIV-1 using CD4+ T- cells to replicate. The process begins
when a free HIV-1 virion attaches to the surface of the CD4+ cell and causes a fusion which result
in the insertion of its viral genome. From here, the genome is reversed transcribed, integrated, and
forms a new virion. The virion is not mature until the viral protease cleaves itself from the newly
translated polyprotein and proceeds to cleave and form proteins that are required for the replication
cycle. (Adapted from www.drcin.com).
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1.5 STANDARD CARE
As of late 2012, there has been a 30% decrease in AIDS related deaths due to highly active
antiretroviral therapy (HAART) [16]. Major risk factors for death by AIDS include a viral load
that is greater than 400 copies/ mL and a CD4+ T cell count less than 200 cells/mL [16]. HAART
subdues HIV-1 replication. This antiviral therapy consists of three drugs that target separate stages
of the HIV-1 life cycle: 2 nucleotide reverse transcriptase inhibitors, a non-nucleotide reverse
transcriptase inhibitor, integrase inhibitor, or protease inhibitor [17–19]. HAART provides
treatment options for both naive and experienced patients. The treatment can decrease plasma
concentrations of viral RNA to undetectable levels, increase amounts of CD4+ T cells, and decrease
the occurrence of HIV-1 related diseases (such as cancer) and excess mortality [16].
Though HAART decreases the viral load below detectable levels, it does not eradicate the
virus entirely due to viral latency and antiretroviral resistance. Post integration HIV-1 latency is a
proviral complex that forms in resting CD4+ T cells. CD4+ T cells that form this complex go
undetected by the immune system [20]. Once these cells are activated by recall antigens or
cytokines, the proviral complex can produce a virus that is able to replicate efficiently [21].
Although rare, HIV-1 viral latency is established during an acute infection (a few days after
exposure) [22]. Viral resistance also makes it impossible to eradicate HIV-1 entirely. HAART uses
drugs that target different stages in the viral life cycle and the replication enzymes. The replication
enzymes develop genetic mutational pathways that result in resistance to the inhibitor thus
allowing the proteins to evade treatment. Over time, the enzyme will completely resist the inhibitor
but continue to aid in the replication process. [23][24][25][26]. In order to keep these
complications under control, the various HAART regimens must last for the patient’s lifetime
[16][18].
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1.6 HIV-1 REPLICATION PROTEINS
There are three enzymes that are required for HIV-1 replication to be effective: reverse
transcriptase (RT), integrase (IN), and protease (PR). The functions of these enzymes makes them
major protagonist in HIV-1 infection. RT produces a complimentary DNA strand from the viral
RNA template; IN integrates the viral genome into the host cell’s genome; and PR generates key
counterparts for maturing virus particles that enable them to continue the replication process [27,
28], [29].
1.7 HIV-1 INTEGRASE
HIV-1 IN inserts reverse transcribed viral DNA (vDNA) into the host cell genome. It is
encoded by the end of the pol gene of the HIV-1 genome and functions as a multimeric protein
[30, 31]. The 288 residues (32 kDa) of HIV-1 IN form three functional domains: the N- terminus
domain, the catalytic core domain (CCD) and the C- terminus domain (Fig. 1-3)[31]. The Nterminus domain (residues 1-49) contain an HHCC motif that binds Zn2+; this “zinc finger”
homologue stabilizes the protein’s quaternary structure (Fig.1-3) [32–35]. The catalytic core
domain (residues 50-212) contains a DD35E motif (the catalytic triad) that coordinates two Mg2+
cofactors in the presence of its substrate. In the apoprotein, one Mg2+ is coordinated between D116
and D64. Once the vDNA is present, a second Mg2+ is coordinated between D64 and E152 [36,
37]. Molecular dynamics experiments and crystallographic studies have revealed a flexible surface
loop conformation that enters the active site during IN’s reaction with vDNA [38, 39]. This loop
is named the 140’s loop because it consists of residues 138-152 [38, 40]. These residues participate
in catlysis and substrate binding reactions making it a vital part of IN’s enzymatic activties [40–
43]. The C- terminal domain (residues 213- 288) interacts both specifically and nonspecifically
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with vDNA ensuring stability of the HIV-1 IN and vDNA (IN•vDNA) complex throughout
catalysis (Fig. 1-5) [31],[37],[44]
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Figure 1-5: The structure of HIV-1 IN. HIV-1 IN consists of 3 functional domains termed the Nterminus domain (NTD), the catalytic core domain (CCD) and the C- terminus domain (CTD). All
three domains have been crystallized in pairs or truncated, but there is no crystal structure of the
protein as an entity. (Adapted from Delelis et al., 2008)
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1.7.1 HIV-1 IN MECHANISMS OF CATALYSIS
IN generates the proviral status of HIV-1 by catalyzing 3’ processing and strand transfer
(Fig. 1-6) [45–48].
In the cytoplasm of an infected cell, after the viral RNA is reverse transcribed into viral
cDNA (vDNA), the autonomous 3’ processing reaction begins (Fig.1-6a and b). During 3’
processing, dimeric IN specifically binds to the U3 and U5 regions of the long terminal repeats
(LTR) of the vDNA (adjacent to a conserved CA dinucleotide) and catalyzes an endonucleolytic
cleavage reaction resulting in the release a dinucleotide and the exposure of reactive 3’ hydroxyl
groups [31][45, 49, 50].
After 3’ processing, the recombinant IN and vDNA complex (IN•vDNA) forms the preintegration complex (PIC), a 61 Å diameter complex that includes other viral and intracellular
proteins and aids in nuclear transport [15]. Once the PIC is in the nucleus, the strand transfer
process begins [51–53],[54].
Strand transfer is the mechanism where IN covalently inserts vDNA in to the hDNA (host
DNA) (Fig. 1-6c and d). IN (in its dimer of dimers conformation) disrupts the phosphodiester
bonds of the hDNA via nucleophilic attack by the reactive 3’hydroxyl groups of the 3’ ends of the
vDNA [2, 20, 21]. This reaction occurs simultaneously with 5 base pairs between the two points
of insertion indicating that the reactive hydroxyl groups attack the hDNA at its major grooves [28,
31, 55, 56],[15].
After stand transfer, the product consists of a 5’ overhang and 5 base pair gaps (Fig. 1-6e).
The 5’ dinucleotide overhangs (resultant of the 3’ processing mechanism) are cleaved and the 5
base pair gaps near the points of insertion are filled by cellular enzymes [31, 46]. In vitro studies
have found that HIV-1 IN in the core catalytic domain catalyzes a disintegration mechanism which
is the opposite reaction of strand transfer where the viral DNA is released from the host cell
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genome [57–59]. It is suggested that IN performs the disintegration mechanism to facilitate the
cleavage of the 5’ overhang, a step which is required for integration of vDNA to be complete [46].
Although this has been observed in vitro, it has not been proven to take place in vivo [31].
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Figure 1-6: HIV-1 IN catalytic activities. HIV-1 IN catalyzes two autonomous reactions: 3’
processing and strand transfer. During the 3’ processing reaction, IN catalyzes an endonucleotyic
cleavage of the 3’ ends of the reverse transcribed vDNA in the cytosol. During the strand transfer
reaction, IN covalently inserts vDNA in hDNA via nucleophilic attack. (Adapted from Delelis et
al., 2008)

16

1.7.2 THE PRE- INTEGRATION COMPLEX
The formation of the PIC complex is essential for efficient viral replication; it ensures that
integration of the viral genome is successful. PIC formation starts with the reverse transcriptase
(RT) complex. Throughout the early steps of the life cycle, RT, IN, vDNA, and other viral and
cellular proteins are a part of a larger complex. After RT transcribes vRNA (viral RNA) into
vDNA, it is degraded from the assembly as it approaches the nucleus via the actin network and
and PIC is formed. PIC aids in the translocalization of IN•vDNA into the nucleus [15, 60, 61].
1.7.2.1 IN•VDNA COMPLEX DURING 3’PROCESING AND STRAND TRANSFER
Because the full length structure of HIV-1 IN has not been determined due to IN’s
interdomain flexibility and high insolubility, the prototype foamy virus integrase (PFV IN)
homology model and many biochemical assays have been used to model the complete structure
of the IN•vDNA complex. Based on crystal structures of PFV IN in complex with vDNA and also
in vitro studies performed on the full length HIV-1 IN, the substrate pocket has been proposed to
consist of all three functional domains; the whole enzyme in its dimer and multimeric form is
required for substrate binding (Fig. 1-7) [62, 63]. Monomer-1 (IN1) and monomer-2 (IN2) bind
the U5 and U3 LTR in the hDNA, respectively. Monomer 1’ (IN1’) and monomer 2’ (IN2’)
domains are required for stability during the catalytic mechanisms (Fig. 1-7).
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Figure 1-7: HIV-1 IN binding to vDNA. The 3D model of HIV-1 IN in complex with vDNA by
Dolan et al. suggest that IN1 (gray) active site is used to insert the U5 LTR 3’ end (green) into the
hDNA (orange) and IN1’ (black) promotes stability during the reaction. IN2 (orange) active site
is used to insert the U3 LTR 3’ end (blue) into the hDNA and IN2’ (green) promotes stability for
this process. (Adapted from Dolan et al., 2009)
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During the 3’ processing reaction, IN makes specific and nonspecific interactions with its
vDNA substrate. IN interacts with the heterocyclic bases of codon A17. This interaction
destabilizes the interaction between nucleotide 17 and 18 (thymine 18 and adenosine 17). The
destabilization results in a high 3` processing rate. Base pairs at positions 8-11 have been shown
to be important for 3’ processing. Residues 186-193 make up a flexible loop conformation that is
located near the C-terminal end of the CCD. These residues bind specifically with the minor groove
of the vDNA at positions 8- 11. Residues 246- 250 of IN1 and residue 20 of IN2 interact with the
backbone of position 8’- 11’. These specific interactions consist of basic residues in the C-terminus
and the phosphodiester backbone of the vDNA’s LTR. Residues 256- 264 in the C-terminal
domain of IN2 nonspecifically interact with the bases at position 3’ and 4’. Residues R262, R263,
K244, G247, Q53, and V54 of IN 2 interact with the phosphodiester backbone of nucleotides at
position 5-7. These interactions with base pairs 3-7 are nonspecific and only promote stability
among the complex during catalysis [62, 64, 65].
IN makes specific and nonspecific interactions with viral DNA during strand transfer.
When IN is in its multimeric form, the LTR of the vDNA and acceptor hDNA interact with two
adjacent subunits (monomer 1 (IN1) inserts U5 and monomer 2 (IN2) inserts U3). The interactions
between IN and the LTRs of U3 and U5 mirror one another. IN binds specifically to the LTR- LTR
junction of the vDNA via residues 143, 148, 156, 159, 160, 230, 246, 262, 263, and 264; these
residues have been observed in molecular models to be near the six base pairs of the LTR and the
ends of the processed vDNA 3’ [56, 62, 64, 66]. A17 is within hydrogen bonding distance of the
Mg2+ and its phosphate group forms hydrogen bonds with N155, K159 and T66. C16 is in the
active site, adjacent to K156 and its carbonyl group points towards Q148 of the 140s loop. K156’s
side chain forms hydrophobic interactions with the deoxyribose ring of C16 and it also interacts
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with G4`. G4` forms specific interactions with Q148 via is carbonyl group; this interaction would
account for IN active site’s specificity for this base pair. T3` is flipped out by Q146 of the active
of IN1 causing it to interact specifically with Q53 and N144 in IN2 [56, 62, 64, 66].
Throughout the strand transfer reaction, the 140s loop acts as a plough, keeping the U5 and
U3 vDNA ends separated. This separation is due to the 5 base pair gap generated by insertion of
the vDNA into the hDNA [56, 62, 64]. When the 140s loop residues are altered in ways that
decrease mobility of the loop, viral activity is decreased substantially [40, 66].
The preferred region of insertion for IN on the hDNA is typically an area where the
phosophodiester backbone is bent and slightly unwound along its major groove. Residues S119,
N120, C130, W132, and K159, (located along the cleft of the dimer IN) have been reported to
interact with hDNA during the strand transfer reaction. IN binding is mediated through the
phosphodiester backbone of hDNA that is wrapped around nucleosomes [54, 62, 64].
1.7.2.2 PROTEIN- PROTEIN INTERACTIONS
For HIV-1 IN activity to be efficient, the pre-integration complex must contain cellular and
viral proteins that stabilize IN and stimulate its activity.. Investigators have found that PIC
complexes are karyophilic; host cell proteins direct PIC complexes through the nuclear pore
(reviewed in ref. [15]). The viral proteins that take part of the PIC are IN (in complex with donor
vDNA and highly karophilic), matrix proteins (regulates integration), Vpr (mediates the nuclear
import of PICs in slowly or non-dividing cells, and stimulates transcription of viral LTRs and
regulates cellular apoptosis [15, 61, 67].
Host cell proteins that have been identified as part of the PIC are as follows: barrier-toautointegration factor (BAF) protects vDNA from autointegration and stimulates intermolecular
recombination when target DNA is located; survival motor neuron–interacting protein 1 (Gemin2)
stimulates reverse transcription and nuclear import of the PIC; cellular acetyltransferase (p300)
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acetylates IN and controls its activity; the nonhistone chromosomal protein HMG I(Y) brings the
vDNA ends together in the active site and acts as a sensor for regulatory input of vDNA during
strand transfer; chaperonin hHSP 60 stimulates IN activity and protects IN from denaturation;
WD- 40 repeat protein human EED plays a role in intracellular and nuclear transport; importin 7
(imp7) contributes to nuclear import and reverse transcription; transcriptional activator integrase
interactor 1 (INI1) which stimulates integration and targets vDNA to active genes, lensepithelium- derived growth factor(LEDGF-p75) tethers IN to chromatin, protects it from
denaturation and stimulates integration; uracil DNA glycosylase (UDG) participates in nuclear
translocation of the PIC [68–78].
1.7.3 HIV-1 IN INHIBITORS
Integrase inhibitors (INIs) decrease the replication rate of HIV-1 RNA by effectively
disrupting mechanisms that IN performs during the HIV-1 life cycle. INIs have either been
classified as strand transfer inhibitors (INSTIs) or allosteric inhibitors (NCINIs) [79],[80].
Since there is no full length structure of IN interacting with INSTIs, various biochemical
assays have been performed to determine the mechanism of action, binding modes, and therapeutic
index of INSTIs [37, 81]
INSTIs consist of planar diketo acid (DKA) derived bioisoteric scaffolds that chelate the
active site Mg2+ and a hydrophobic component that interacts with side chains of residues and
vDNA in a ternary binding pocket that competes with the binding of vDNA (Fig. 1-8) [80][81] .
The DKA moiety analogues enable the INSTI to compete with vDNA for the catalytic binding
pocket and the halogenated hydrophobic component increases specificity and affinity of the
inhibitors target protein [37, 80–82]. The chelating hydroxyl groups of the DKA analogues chelate
the Mg2+ ions. The binding of INSTIs halobenzyl ring (the hydrophobic component) via Van der
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Waals interactions in the pocket of the active site where vDNA adenosine (A17) resides displaces
the vDNA and stabilizes the molecule, therefore disengaging the IN•vDNA complex [37, 80, 83].
The vDNA is then circularized by cellular enzymes and persists in the nucleus for an undetermined
duration[37].
The proposed binding site for INSTIs is based on INSTI resistance profiles. INSTIs bind
to IN only if the vDNA is present in the active site during the assembly of the PIC; after 3’
processing but before strand transfer [37, 80, 81]. Due to these mechanisms of action and binding,
INSTIs are considered “metal dependent” compounds and “interfacial inhibitors” [37, 82].
INSTIs have a resilient time- of- drug addition profile; these compounds have been
observed to increase the formation of cDNA and hence decrease integration. Mutations have been
found in drug resistant INs; and, in vitro, mutated viruses treated with an INSTI have been shown
to be inactive, which explains the high therapeutic index of INSTIs for IN [37].
Currently there are three HIV-1 inhibitors (INIs) approved by the Food and Drug
Administration (FDA): Raltegravir (RAL), elvitegravir (ELV), and dolutegravir (DTG). All three
INIs are considered integrase strand transfer inhibitors (INSTIs) due to their specific inhibition of
the stand transfer process [84–86].
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1.7.3.1 FDA APPROVED HIV-1 INTEGRASE STRAND TRANSFER INHIBITORS

Figure 1-8: FDA approved INSTIs. The FDA has approved three INTIs for commercial usage: a:
Raltegravir (RAL), b: Elvitagravir (ELV), and. c: Dolutetravir (DTG). The pharmacophores
encircled in green are protruding scaffolds from RAL (oxadiazole ring) and ELV (1hyrdroxymethyl2- methylpropyl group) DKA core; blue are the halobenzyl groups of each INSTI;
and red are the DKA analogues and the chelating oxygen atoms.
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1.7.3.2 RALTEGRAVIR
On October 7, 2007, raltegravir (RAL) became the first INSTI to be approved by the Food
and Drug Administration. RAL was developed by Merck and Co. under the generic name
Insentress; the patent expires October 3, 2023 [87],[88].
RAL has a hydropyrimidone that acts as RAL’s DKA analogue and a carboximide side
chain that acts as the heteroatomic feature. RAL’s oxadiazole ring makes a ∏ stacking connection
with Y143 and P145 42,,58,[89]. RAL’s halogenated benzyl ring extends into the tight pocket created
by the A17 nucleotide of the vDNA[90].
1.7.3.3 ELVITEGRAVIR
Elvitegravir (ELV)) is a cobicistat boosted INI that is administered in a quad pill
formulation with the RT inhibitors tenofovir and emtricitabine called Stribild [91]. Stribild was
developed by Gilead Sciences, which licensed the inhibitor from Japan Tobacco in 2008.
Elvitegravir was approved by the Food and Drug Administration on August 27, 2012 and its patent
expires in 2029 [92, 93].
ELV has a quinolone-3- carboxylic group which serves as a substitution for the DKA
moiety and a carboxylic/ β- ketone scaffold that serves as the chelating heteroatoms [94]. ELV’s
1-hydromethyl-2-methylpropyl groups serves as a substitution for RAL’s oxadiazole ring which
interacts with Y143 and P145 via Van der Waals interactions [90, 95]. ELV also contains a linker
that connects the DKA bioisoteric component to its flurobenzyl ring that interacts with E152 and
vDNA [43, 56, 94].
1.7.3.4 DOLUTEGRAVIR
Dolutegravir (DTG) is a second generation INI that was approved by the Food and Drug
Administration on August 12, 2013. DTG (formerly known as S/GSK1349572) was developed by
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ViiV Healthcare and is known by the generic name Tivicay [96],[97]. The patent expires October
5, 2027 [97]. DTG is considered a second generation INI due to its ability to retain activity against
viral strains that result in viral resistance to RAL and ELV in vitro. It is the first unboosted INSTI
on the market[98–100].
DTG has a tricyclic carbomoyl pyridine DKA analogue that contains three coplanar oxygen
atoms which act as the chelating agents [98]. DTG’s hydrophobic component is a diflourophenyl
ring which is attached to an extended flexible linker that occupies the tight pocket near the active
site. This diflourophenyl ring interacts with carbon atoms of the catalytic residues E152 and Q148
via Van der Waals contacts. This extended linker region digs deeper into the tight evacuated pocket
enabling DTG to make more intimate interactions with the vDNA. It has the ability to adjust its
position and conformation when there is a structural change in IN’s active site. DTG’s tricyclic
chelating core extends toward G118. DTG spans the full width of the active site but only spans
half of its height. [41, 43].
1.7.3.5 CABOTEGRAVIR (GSK1265744)
Cabotegravir (CAB) is similar to DTG with a carbamoyl pyridine DKA analogue and
diflourophenyl pharmacophores [101, 102]. Administration of CAB is different from all of the
existing INIs on the market. While it is administered orally, it is also being tested as a monthly
intramuscular injection that includes the NNRTI TMC278-LA [103]. ViiV Healthecare has run
eight phase 1 and phase 2 trails to determine the pharmacokinetic parameters of CAB; they
administered a two-drug regimen every 4 to 8 weeks via an intramuscular injection (800 mg) and
oral (30 mg) formulations of CAB and rilpivirine (a non-nucleoside inhibitor) [103].
1.7.3.5 NON - CATALYTIC INTEGRASE INHIBITORS
1.7.3.5.2 BI-224436
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Another INI currently in clinical trials is BI-224436 which was developed by Boehringer
Ingelheim [104]. BI-224436 (BI2) disrupts the interactions between IN and LEDGF/p75 protein
by binding to the allosteric binding pocket, which is located in the CCD dimer interphase at
residues A124, T125, A128, E170, and H171; it is the first NCINI to go into clinical trials [63,
105].[106].
BI2 has 3 substituents that provide metabolic stability (C4), potency (C7) and binding (C3
and C4). The core pharmacophore of BI2 is a C4 moiety that consists of a hybridized chromane
and quinolone arene system which provides potency and metabolic stability; C3 consists of an
alkoxyl group that fills the hydrophobic pocket and provides favorable binding affinity and
increased potency; C7 is connected to a hydrogen which enables potency serum shifts [106].
1.7.4 ANTIRETROVIRAL ACTIVITY
1.7.4.1 RAL RESISTANCE
Major mutation pathways that are associated with IN resistance to RAL are [Q148H/K/R]
± [G140S/A] and {E138K/A], [N155H]±[E92Q], and [Y143C/R]± [T97A] [107–110]. Primary
mutations Q148H/R/K decreases IN susceptibility to RAL by 5- to 50- fold whereas the double
mutant Q148H/R/K and G140S/A reduces susceptibility by more than 100- fold; E138K/A is
selected in combination with the primary mutation Q148H [111]. These genetic pathways have
been associated with therapeutic failure. This decreased potency has been shown to result in near
WT viral loads [111–114]. The mutation Y143C/R reduces susceptibility to RAL when selected
alone [109]. When the double mutant Y143C/T97A is selected, IN susceptibility to RAL is reduced
by more than 100-fold [109, 115]. [N155H] has been associated with RAL failure in patients
because it restores viral activity to near WT levels [114].
1.7.4.2 ELV RESISTANCE
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The mutational pathways that are associated with the highest level of resistance to ELV are
the primary mutants [Q148H/K/R] ± [G140S/A], [N155H]±[E92Q], and [T66I/A/K] ± [S147G]
[115–117]. According to in vitro and in vivo studies, the primary mutations Q148H/R/K, just as
with RAL, reduce susceptibility to ELV and are associated with therapeutic failure [118, 119].
[T66A/I/K] is a primary mutation that was observed to be selected by IN when under ELV pressure
in preclinical trials. An in vivo study done on patients that had previously failed treatment with
ELV, mutation [N155H] was observed to be selected within the first two weeks of the study (n=5
out of 16) [120].
1.7.4.3 DOLUTEGRAVIR RESISTANCE
Just as with RAL and EVG, IN mutates in response to treatment with this second generation
inhibitor. but the mutations produce minimal viral resistance. According to the Stanford HIV-1
Drug Resistance Database, codons 92,138,140, and 148 acquire mutations that are responsible for
IN resistance against DTG [115, 117].If the primary mutant Q148H/R/K and accessory mutants
G140S/A and E138K/A are alone, there is no clinically significant reduction in susceptibility to
DTG [54]. In vitro, IN has been shown to select the primary R263K mutation along with H51Y,
M50I, and E138K as secondary mutations [106, 107].
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Table 1-1: HIV-1 integrase resistance mutations
M50
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H
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K
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Q

A

G

H/R/

H
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K
I
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Y

K
A/K

S/A

H

K
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CHAPTER 2 : MATERIALS AND METHODS
2.1 HIV-1 INTEGRASE CATALYTIC CORE DOMAIN SYSTEM PREPARATION FOR
MOLECULAR DYNAMICS SIMULATION
The WT catalytic core domain of HIV-1 IN was obtained from the Protein Data Bank
(PDB: 1BL3). Chain C of 1BL3.pdb was used to construct homology models for the following
mutants: [Q148H], [Q148H/G140S], [Q148R], [Q148H/G140S], [Q148R/G140A], and
[N155H/E92Q]. The coordinates from the original PDB model (1BL3) and the new models were
merged together to obtain crystallographic waters in the new models [42, 121].
The IN structure requires Mg2+ metal ions in the active site (coordinated between the DDE
motif). 1BL3 contained only one Mg2+ ion in the active site (coordinated between D64 and D116);
therefore, the PFV IN crystal structure (PDB: 3OYA) was superimposed with the models to
incorporate the other Mg2+ ion between residues D64 and E152 [42, 90].
Models of the INSTIs RAL, ELV, and DTG were obtained from the Zinc Database
(http://zinc.docking.org/).

Each

INSTI

was

submitted

to

Paramchem

(https://cgenff.paramchem.org) for the generation of topology files and parameter files [122].
In order to properly coordinate the INSTIs RLT, ELV and DTG into the integrase active
site, homologous structures containing the three inhibitors were obtained. The coordinates from
the PFV IN complexed with RAL (PDB: 3OYA), ELV (PDB: 3L2U) and DTG (PDB: 3S3M)
were used to manually dock the inhibitors into the active site of the CCD using the VMD TK
console [41, 56, 90, 121]. The system was placed in a TIP3P water box (dimensions: 70x72x70
Å) and was neutralized with MgCl2 [121].
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2.2 ENERGY MINIMIZATION AND MOLECULAR DYNAMICS SIMULATIONS
Energy minimization of the systems was accomplished using the conjugant gradient
method. The initial temperature of the system was set at 70K followed by an increase to 310K in
5K time steps [42, 123].
All of the MD simulations were performed with NAMD 2.9 for 40ns utilizing the
CHARMM36 force field. Van der Waals (vdW) interactions were cut off at a 12Å distance. Long
range electrostatic interactions were calculated using the Particle-Mesh Ewald (PME) method.
Equations of motion were incorporated with a 2fs time step [123, 124].
The conserved NPT (model, pressure and temperature) ensemble was used to perform the
simulations. To keep the system at a constant temperature of 310K, Langevin dynamics were used
(the Langevin damping coefficient was set at 5ps-1) and the Nose- Hoover Langevin piston method
was used to keep the pressure of the systems constant at 1atm [124, 125]. Twelve processors were
used from the WSU high performance scientific computing GRID (www.grid.wayne.edu) to
enable the MD simulations to run in parallel.
2.3 ANALYSIS
The molecular dynamics trajectory was loaded into VMD [121]. The VMD suite’s timeline
tool was used to calculate the RMSD of each Cα atom for the last 5ns of the simulation.
2.4 FULL LENGTH HIV-1 INTEGRASE SYSTEM PREPARATION FOR MOLECULAR
DYNAMICS SIMULATION
The full length HIV-1 integrase structure has not been successfully crystallized and solved.
Therefore, the full length HIV-1 integrase model was generated based on the crystal structure of
the prototype foamy virus (PFV) structure (pdb: 3OYA). The full length HIV-1 integrase sequence
was submitted to the Swiss-Model server using chain A of the PFV structure (pdb: 3OYA) as a
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template [126, 127]. PFV has the same active site conformation with the DDE motif aiding in
catalysis and functional domains as HIV-1 IN making it a suitable template (Fig. 2-1). The
previously published integrase structures for the CCD (pdb: 1BL3), NTD, plus CCD (pdb: 1K6Y),
and CTD plus CCD (pdb: 1EX4) domains were then superposed onto the SwissModel structure.
The linker regions generated from the SwissModel server were merged with the known
crystallographic structures to generate our full length HIV-1 integrase model. After generation of
the full length model, each system was prepared for simulation as previously described [42].
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a
.

b
.

Figure 2-1: Full length HIV-1 integrase modeled from PFV integrase. (a). Prototype foamy
virus integrase from PDB 3OYA with the CCD shown in blue, CTD shown in magenta, NTD
shown in yellow and NED shown in dark grey. (b). Full length model of HIV-1 integrase with
same color scheme for each domain. The HIV-1 IN model was built from the CCD structure
(1BL3), NTD and CCD structure 1K6Y, and the CTD and CCD structure (1EX4).
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2.5 ANALYSIS
The last 5ns of the trajectory was loaded into VMD 1.9.2. Then, for each simulation the
backbone RMSD of each residue was calculated using the timeline tool with the first frame post
energy minimization acting as a reference. The Ramachandran analysis tool was used to analyze
the φ and ψ angles of the 140s loop residues over the duration of the trajectory. The depicted
residues are those that showed significant φ and ψ angle differences to what was observed in our
prior work [42].
Interactions between the ligand, viral DNA and protein were quantified to determine
differences in molecular recognition. LigPlot+ version 1.4.5 and Nucplot v.1.0 were used to
analyze INSTI-protein and viral DNA-INSTI interactions, respectively [128] [129]. The number
of interactions were measured every 2000th frame of the 20,000 frame simulation and were
averaged over the resulting ten frames.
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CHAPTER 3 : REDUCED HIV-1 INTEGRASE FLEXIBILITY
CORRELATES WITH RALTEGRAVIR, ELVITEGRAVIR AND
DOLUTEGRAVIR DRUG RESISTANCE
3.1. INTRODUCTION
HIV-1 integrase (HIV-1 IN or IN) is a multimeric enzyme that integrates the HIV-1
genome into the DNA of infected CD4+ T-cells. HIV-1 IN is encoded by the end of the pol gene
[37, 47]. This 288 amino acid enzyme (32 kD) consists of three functional domains: the N-terminal
domain (NTD), catalytic core domain (CCD), and C-terminal domain (CTD). The CCD has a
catalytic triad (D64, D116, and E152) that coordinates two Mg2+ and a flexible catalytic loop (140s
loop) that is required for activity [40, 130]. HIV-1 IN catalyzes two autonomous reactions termed
3’-processing and strand transfer. 3’processing involves endonucleolytic cleavage of the 3’ ends
of the viral DNA by dimeric IN resulting in the exposure of reactive hydroxyl groups [130]. Strand
transfer mediates the covalent insertion of viral DNA into the host cell DNA through a
transesterification reaction using the reactive hydroxyls produced via 3’ processing as nucleophiles
[31, 51, 53].
Currently there are three HIV-1 IN inhibitors (INIs) approved by the Food and Drug
Administration (FDA) for clinical use: raltegravir (RAL), elvitegravir (ELV), and dolutegravir
(DTG). All three drugs function as strand transfer inhibitors (INSTIs) [37, 80–83, 131] and have
a planar diketo acid (DKA) derived bioisoteric scaffold that chelates the active site Mg 2+ and a
halogenated hydrophobic component in the form of a halobenzyl group that increases specificity
and affinity (Fig 1-8 and Fig. 3-1) [80, 82, 95, 132].
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Figure 3-1: HIV-1 integrase (PDB: 1BL3) active site in complex with elvitegravir. Elvitegravir
(ELV) diketo acid motif chelates the active site Mg2+ in HIV-1 IN’s active site. ELV is shown as
yellow sticks, Mg2+ are shown as blue spheres, the IN catalytic triad is shown as sticks, and the
drug resistance mutations are shown as purple sticks.
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According to the Stanford HIV Drug Resistance Data Base (http://hivdb.stanford.edu)
RAL and ELV share a cross resistance profile. The mutations that IN acquires when challenged
with RAL or ELV include the single mutants [Q148H] and [Q148R] and the double mutants
[N155H/E92Q], [Q148H/G140S], and [Q148R/G140A] [112, 115, 118, 133]. These mutation
pathways decrease IN susceptibility to RAL and ELV and increase therapeutic failure [31, 41, 43,
111–114, 118, 134–140] .

In our previous work, we studied the protein flexibility and

secondary structural alterations that occurred in the CCD domain of WT HIV-1 IN [Q148H/R]
and [Q148H/R, G140S/A], in a 10 ns molecular dynamics simulation when bound to RAL [42].
We found that the mutants displayed a decreased flexibility relative to the WT model. We also
discovered that the 140s loop in each mutant adopted a rigid hairpin conformation that functioned
as a gate and decreased the RAL residency time [42]. To further investigate these findings, we ran
a 40 ns molecular dynamics simulation on the IN CCD of WT, [Q148H/R], [Q148H/R, G140S/A]
and [N155H, E92Q] as apoproteins and in complex with RAL, ELV, and DTG to investigate a)
the effect that these mutations have on protein flexibility, b) how IN flexibility affects INSTI
complexes and c) to determine if there is a relationship between IN flexibility and INSTI
resistance. A decrease in flexibility is observed in the apoprotein mutants relative to the apoprotein
WT. The mutant forms of IN that display the most resistance in viral susceptibility studies display
high RMSD values in the 140s loop region relative to their corresponding WT-INSTI complex.
These findings suggest that the conformational changes that occur in these mutants decrease the
flexibility of the CCD which changes the shape of the active site. When this occurs, IN-INSTI
complex interactions are weakened, ultimately causing drug resistance.
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3.2 RESULTS
To investigate the effects that [Q148H], [Q148R], [Q148H, G140S], [Q148R, G140A] and
[N155H, E92Q] mutations had on the flexibility of the CCD of HIV-1 IN, the RMSD of each
residue in each structure was calculated. Calculations were derived from the last 5 ns of a 40 ns
simulation of the CCD as an apoprotein and also in complex with RAL, ELV, and DTG. From
these data, the effect that [Q148H/R], [Q148H/R, G140S/A] and [N155H, E92Q] had on HIV-1
IN CCD flexibility and the relationship between IN flexibility and INSTI resistance was identified.
According to the results, the drug resistance mutations produced a less flexible apoprotein CCD
relative to the WT apoprotein. As result, the 140s loop becomes more flexible in versions of mutant
IN that display a higher level of resistance in reported in vitro work. This suggest that INSTIs
binding mode to the 140s loop is altered as a result of the active site structural change.
3.4.1 MUTATIONS [Q148H], [Q148H, G140S], [Q148R], [Q148R, G140A] AND [N155H,
E92Q] INCREASE THE RIGIDITY OF THE HIV-1 INTEGRASE PROTEIN
As shown in Fig. 3-2, the apoprotein IN mutants are less flexible than apoprotein WT IN.
Also, in Table 2, the 140s loop is less flexible in the mutants that in WT IN.. These results suggest
that conformational changes that occur is in the CCD changes the shape of the active site.
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Figure 3-2: Flexibility (RMSD) of the apoprotein HIV-1 integrase models. The VMD suite
timeline tool was used to calculate the root mean square deviation of Cα (RMSD) in each residue.
The apoprotein IN displays the most flexibility relative to the various mutants.
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Table 3-1: The RMSD of the 140s loop of apoprotein wild type and mutant HIV-1 integrase
Mutants studied

140s loop RMSD

WT

9.30Å

Q148H

5.27Å

Q148H, G140S

4.72Å

Q148R

2.58Å

Q148R, G140A

3.35Å

N155H, E92Q

4.05Å

Note: The average root mean square deviation (RMSD) values for each complex was used as an indicator of
HIV-1 integrase flexibility. The mutant HIV-1 integrase are less flexible than the wild type HIV-1 integrase.
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3.4.2 HIV-1 INTEGRASE STAND TRANSFER INHIBITOR RESISTANCE
CORRELATES WITH THE FLEXIBILITY OF THE 140S LOOP
To investigate the relationship between IN flexibility and INSTI resistance, the RMSD of
the 140s loop in each mutant in complex with RAL, ELV, and DTG were calculated (Fig. 3-3ad). Results indicate that the 140s loop is more flexible in IN mutants that display the highest
reported EC50 FC (fold change). These findings suggest that increased rigidity of the mutants
reduces INSTI binding to the 140s loop.
The conformational changes in the CCD caused by drug resistant mutations resulted in
increased flexibility of the 140s loop when in complex with RAL; this observation is indicated by
increased flexibility of the 140s loop in mutants relative to WT RAL complexes (Fig. 3b). As
presented in Table 3, all mutations display an increased EC50 FC value and higher140s loop
RMSDs when under RAL pressure relative to the WT- RAL complex (Table 3). This is an
indicator of weakened interactions between RAL and IN.
The increased rigidity of the CCD caused by mutations increases the flexibility of the 140s
loop in the CCD-ELV complexes. In Table 3, EC50 FC and RMSD values are highest in the
[Q148H, G140S], [Q148R] and [Q148R, G140A] ELV complexes relative to the WT ELV
complex (Fig. 3-3c). These mutants display a correlation between flexibility and resistance (Table
3).
When complexed with DTG, the mutants that exceed the WT EC50 display increased
flexibility in the 140s region (Table 3). As presented in Fig. 3-3d, [Q148H] and [Q148R] in
complex with DTG display decreased flexibility relative to WT-DTG because of the structural
changes. In Table 3, [Q148H, G140S] and [N155H, E92Q] in complex with DTG display the
highest EC50 FC values and an increased RMSD in the 140s loop relative to the WT DTG complex.

40

The effect of [Q148R, G140A] on IN susceptibility to DTG has not been studied in vitro, however,
the 140s loop in this mutant is the most flexible. These data indicates a relationship between HIV1 IN flexibility and resistance.
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Figure 3-3a-d: Flexibility (RMSD) of HIV-1 integrase mutants in complex with raltegravir,
elvitegravir, and dolutegravir. a) HIV-1 IN catalytic core domain outlining the catalytic triad
(highlighted in orange) and the locations of the mutations (E92Q is highlighted in purple, the 140s
loop is highlighted in yellow and α4 is highlighted in cyan). The plots in figure 3-3 display b) root
mean square deviation of Cα (RMSD) of the wild type and mutant IN raltegravir complexes, c)
the RMSD of the wild type and mutant IN elvitegravir complexes; and d) the RMSD of the wild
type and mutant IN dolutegravir complexes. The yellow box enclose the 140s loop.
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Table 3-2: Reported EC50 fold change (EC50 mutant/ EC50 wild type ratio) in vitro data
Mutants

Raltegra Elvitegravir Dolutegravir
vir EC50 EC50
EC50
(fold
(fold change) (fold change)
change)

WT
Q148H

1.0
13±5.0
[113]
>130
[113]
47±9.3
[113]

1.0
7.3±2.3
[113]
>890
[113]
240±91
[113]

1.0
0.97±0.090
[113]
2.6±1.4
[113]
1.2±0.21
[113]

>100
[112]
>130
[113]

>350
[112]
320±39
[113]

Q148H_G140S
Q148R

Q148R_G140A
N155H_E92Q

140s loop
RMSD in
RAL
complexes
(Å)
1.94Å
2.58Å

140s loop
RMSD in
ELV
complexes
(Å)
2.50Å
1.92Å

140s loop
RMSD in
DTG
complexes
(Å)
3.08Å
2.65Å

2.53Å

2.69Å

3.10Å

2.41Å

3.41Å

2.85Å

No data

2.19Å

3.58Å

3.47Å

2.5±1.2
[113]

2.49Å

2.50Å

3.07Å

*Note: These fold changes in EC50 values (ratio: EC50 of mutants/EC50 of wild type) are derived
from reported in vitro studies and correlate positively with our RMSD data. EC50 fold changes for
dolutegravir were substantially lower than both raltegravir and elvitegravir in the presence of
mutations that typically lead to therapeutic failure [112, 113].
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3.3 DISCUSSION
3.3.1 VIRAL ENZYME FLEXIBILITY AND DRUG RESISTANCE
Protein flexibility has been implicated in HIV-1 protease and HIV-1 IN resistance [95, 133,
141, 142]. IN flexibility (especially for the 140s loop) has been shown to be important for catalysis
as well [40, 66, 130, 143]. Previously we found that the IN mutants [Q148H/R] and [Q148H/R,
G140S/A] produce rigidity in the CCD when in complex with RAL. In this study, we observed the
effects various drug resistance mutations had on CCD flexibility and the correlation between our
molecular dynamics simulation results and reported experimental results. IN takes on a rigid
conformation when the mutations are introduced. As a result of the structural alterations, IN’s 140s
loop flexibility is increased in the mutants that display the highest EC50 FCs in table 2.
The highest RMSD peaks in the models are in the 180s loop region (residue 185-195) (Fig.
3-3a). The 180s loop interacts with the minor groove of viral DNA during catalysis; the spike in
RMSD is expected due to the absence of DNA in this study.
3.3.2 DOLUTEGRAVIR RETAINS EFFICACY AGAINST DRUG RESISTANT VIRUS
DTG showed the least sensitivity to the drug resistance mutations studied. The mutant IN
DTG complexes RMSD deviated the least from the WT DTG complex. DTG also displayed the
lowest EC50 FCs in the reported in vitro data (Fig. 3-3d). This is due to DTG’s structural features.
DTG contains the same active pharmacophores as RAL and ELV but structural differences enable
DTG to have a prolonged residency time. DTG contains an extended linker that anchors its
halobenzyl component deeper into the donor DNA’s pocket in the active site and makes more vdW
interactions with the backbone of the catalytic residue E152 causing increased rigidity of the active
site (Fig. 1-8 and Fig. 3-3b) [41]. Also, DTG’s flexible structure gives it the ability to change its
conformation with the active site of mutant HIV-1 IN, prolonging its residency time. These
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features makes DTG less vulnerable to being pushed out of the active site in the resistant strains
of IN.
3.3.3 IN SILICO METHODOLOGY AND DESIGN OF HIV-1 INTEGRASE
INHIBITORS THAT RETAIN EFFICACY AGAINST THE DRUG RESISTANT VIRUS
The correlation between our in silico results and the in vitro reports show that this
methodology can be a useful drug design and screening tool. New experimental inhibitors should
show WT like binding patterns for mutant IN, which, in our studies, has shown minimal resistance.
With this approach, INSTIs could be modified prior to synthesis to promote more rigidity of the
140s loop, minimizing the chance of drug resistance.
To further investigate the mechanism of drug resistance, we studied structural changes in
HIV-1IN mutants [Q148H], [Q148H, G140S], [Q148R], [Q148R, G140A], and [N155H, E92Q].
In particular, changes in the HIV-1 IN 140s loop were examined. We then investigated the
relationship between IN flexibility and drug resistance. Our findings suggest: a) the mutations
cause IN flexibility to decrease, b) mutant INSTI complexes have increased 140s loop flexibility
relative to the WT-INSTI complexes, and c) increased 140s loop flexibility in mutants correlates
with higher in vitro EC50 fold change reported earlier.
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CHAPTER 4 : REDUCED FLEXIBILITY OF FULL LENGTH HIV-1
INTEGRASE CORRELATES WITH DRUG RESISTANCE TO
RALTEGRAVIR, ELVITEGRAVIR, AND DOLUTEGRAVIR
4.1 INTRODUCTION
HIV-1 integrase (IN) is a 32 kD multimeric enzyme that integrates the HIV genome into
the DNA of infected CD4+ T-cells [37, 47]. IN contains three functional domains: the N-terminal
domain (NTD), catalytic core domain (CCD), and the C-terminal domain (CTD) (Fig. 1a). The
CCD contains the catalytic triad (residues D64, D116, and E152) that coordinates divalent metal
ion cofactors (Mg2+, Mn2+) , and a flexible catalytic loop (140s loop) which plays a major role in
IN activity [40, 130] (Fig. 1b). IN catalyzes two autonomous reactions: 3’ processing and strand
transfer. 3’ processing is the endonucleolytic cleavage of the viral DNA 3’ ends by IN resulting in
the exposure of reactive hydroxyl groups [130]. Strand transfer mediates the covalent insertion of
viral DNA into the host cell DNA through a transesterification reaction using the reactive hydroxyl
groups as nucleophiles [31, 51, 53].
Currently there are three HIV-1 IN inhibitors (INIs) approved by the U.S. Food and Drug
Administration (FDA): raltegravir (RAL), elvitegravir (ELV), and dolutegravir (DTG). These
inhibitors function as strand transfer inhibitors (INSTIs) [37, 80–83, 131]. INSTIs consist of a
planar diketo acid (DKA) derived bioisosteric scaffold that chelates the active site Mg 2+ ions, and
a halogenated hydrophobic component that increases specificity and affinity for the IN active site
(Fig. 1b; Fig. 2) [80, 82, 95, 132].
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a.

b.

Viral DNA

Catalytic
core domain

180°

C- Terminal
domain

N- Terminal
domain

Figure 4-1: HIV-1 INTEGRASE HOMOLOGY MODEL AND ACTIVE SITE IN
COMPLEX WITH ELVITEGRAVIR. The full length HIV-1 IN homology model was
used to study secondary structural and molecular recognition differences between mutant
and WT complexes. (a)The ternary complex consisting of viral DNA, the full length
homology model which includes the n-terminal domain (yellow), the c- terminal domain
(magenta), and the catalytic core domain (blue), and a INSTI. (b). The active site of the
full length homology model showing ELV (green sticks) bound, ; Mg2+ are shown as
orange spheres, the catalytic triad is shown in cyan sticks, and the mutant residues are
shown in magenta sticks.
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According to the Stanford HIV Drug Resistance Database [144, 145], RAL and ELV share
a cross resistance profile. IN acquires several resistance mutations under RAL and ELV treatment
pressure including the single mutants [Q148H] and [Q148R] and the double mutants
[N155H/E92Q], [Q148H/G140S], and [Q148R/G140A] [112, 115, 118, 133]. These mutations
decrease IN susceptibility to RAL and ELV and increase viral activity, ultimately leading to
therapeutic failure [31, 41, 43, 111–114, 118, 134–140].
40 ns molecular dynamics (MD) simulations with the full length WT IN and the
[Q148H/R], [Q148H/R, G140S/A] and [N155H, E92Q] IN drug resistant mutants as binary
(protein and viral DNA) and ternary ( protein, viral DNA, and INSTI) complexes were performed
to investigate the following: a) the effect of these mutations on protein flexibility, b) secondary
structural changes produced in the 140s loop, and c) the effect of these mutations on molecular
recognition of the ligand by the protein and substrate. The mutant models displayed reduced
flexibility, alternative 140s loop secondary structure conformations, and altered molecular
recognition patterns compared to the wild-type model. These findings suggest that the decreased
flexibility of the enzyme causes conformational changes in the active site of the mutants that may
result in decreased INSTI binding affinity and residence time.
4.2 RESULTS
Mutations at position 92, 140, 148, and 155 cause decreased flexibility of HIV-1 IN. Our previous
work reported decreased flexibility of the [Q148H], [Q148H, G140S], [Q148R], and [Q148R, G140A]
CCD IN mutants in complex with RAL relative to the WT-RAL complex [42]. To examine whether these
results could be reproduced with the full length model, we performed 40 ns simulations on binary
complexes (protein and viral DNA) of WT and the mutants ([Q148H], [Q148H, G140S], [Q148R], [Q148R,
G140A] and [N155H, E92Q]).
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4.2.1 MUTATIONS DECREASE FLEXIBILITY OF HIV- 1 INTEGRASE
Mutations at position 92, 140, 148, and 155 cause decreased flexibility of HIV-1 IN. Previous work
with the CCD IN reported decreased flexibility of the [Q148H], [Q148H, G140S], [Q148R], and [Q148R,
G140A] mutant IN- RAL relative to the WT-RAL complex [42]. To examine whether these results could
be reproduced with the full length model, we performed 40 ns simulations on binary complexes (protein
and viral DNA) of WT IN and the mutants ([Q148H], [Q148H, G140S], [Q148R], [Q148R, G140A] and
[N155H, E92Q]).
The binary mutant IN-RAL complexes displayed decreased flexibility relative to the WT-RAL
complex as shown in Fig. 4. The average RMSD of the WT, [Q148H], [Q148H, G140S], [Q148R], [Q148R,
G140A] and [N155H, E92Q] complexes are 5.88 Å, 2.29 Å, 2.43 Å, 1.98 Å, 1.97 Å, and 2.10 Å,
respectively. (Fig. 4).
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Figure 4-2: Resistance mutations reduce the flexibility of the IN-DNA binary complexes.
The VMD suite timeline tool was used to calculate the root meant square deviation of Cα
(RMSD) for each residue in the binary mutant and WT complexes. This approach analyzed the
effects that mutants had on HIV-1 IN flexibility. The mutant HIV-1 IN structures are more rigid
than WT IN.
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4.2.2 CHANGES IN 140S LOOP SECONDARY STRUCTURE IN ELVITEGRAVIR AND
DOLUTEGRAVIR COMPLEXES
It was also investigated whether or not transient helix formation occurs in the full length
model as it did previously with the CCD [42] (Fig. 5 and 6). In the IN-ELV complexes, there is
evidence of a transient α-helix conformation in residues 139,146, 147 and 148 in the mutant
structures.

The Ramachandran plots in Figure 5 show residue 148 with φ and ψ angles

corresponding to a β-sheet secondary structure in the WT-ELV complex. However, in the [Q148H,
G140S] and [Q148R, G140A] mutants, residue 148 adopts a α-helix secondary structure. (Fig. 5).
Residue 139 is found in a β-sheet conformation in all complexes except for in [Q148R] where
residue 139 is in a right handed helix (Fig. 5). Similarly, residue 146 is also in a β-sheet
conformation in all complexes except in the [Q148H, G140S] mutant where it exhibits a right
handed helix (Fig. 5). For residue 147, the WT-ELV and [Q148R, G140A]-ELV complexes have
a β-sheet secondary structure. However, in [Q148H], [Q148R], and [N155H, E92Q], residue 147
adopts a left handed α-helix conformation. [Q148H, G140S] adopts a helical conformation as well,
but it is right-handed (Fig. 5). The mutations at residues 92, 140, 148 and 155 cause the 140s loop
(at residues 139, 146, 148 and 147) form a loop that could reduce drug potency; this was observed
in prior work with the CCD in complex with RAL [42]. Due to the location of the 140s loop, most
likely these residues form a β-strand when in the β-sheet conformation rather than a β-sheet. It is
possible that a transient α-helix reduces the flexibility of this region more than a β-strand.
Therefore, the reduced flexibility of this region could be attributed to these transient
conformational changes.
Evidence of a transient α-helix conformation is also present for the mutant structures at
residues 146 and 148 when complexed with DTG. Residue 148 displays a β-sheet conformation
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in the WT-DTG complex, whereas in [Q148H, G140S], [Q148R, G140A] and [N155H, E92Q],
residue 148 corresponds to the right handed α helix conformation (Fig.6). Residue 146 in the WT
DTG complex is in a β sheet conformation whereas it is in a right handed helix in the [Q148R] and
[N155H, E92Q] complexes (Fig. 6).
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Figure 4-3: Secondary structure changes of 140s loop residues in ELV complexes. The
Ramachandran tool in the VMD suite was used to calculate φ and ψ angles of the 140s loop
residues in wild type and mutant HIV-1 IN in complex with elvitegravir over the 20000 frame
trajectory. Residues displaying the most secondary structural differences are shown.
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Figure 4-4: Secondary structure changes of 140s loop residues in DTG complexes. The
Ramachandran tool in the VMD suite was used to calculate φ and ψ angles of the 140s loop
residues in wild type and mutant HIV-1 IN in complex with dolutegravir over the 20000 frame
trajectory. Residues displaying the most secondary structural differences are shown.
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4.2.3 DECREASED FLEXIBILITY OF THE HIV-1 IN MUTANTS RESULT IN
ALTERED MOLECULAR RECOGNITION OF HIV-1 INTEGRASE INHIBITORS
Notable changes in molecular recognition of RAL, ELV and DTG by IN occurred in the
IN mutant ternary complexes. Interactions between the INSTI and IN, and the INSTI and DNA
were quantified every 4 ns of the 40 ns simulation by LigPlot+ and NucPlot and were averaged
over these frames[128, 129]. Decreased flexibility of mutant IN alters the binding mode of RAL
to the protein and the viral DNA (Table S1). All mutant complexes display a decrease in the
number of hydrogen bonds compared to the WT-RAL complex, suggesting an altered hydrogen
bonding network in the mutant complexes. The [Q148R, G140A] and [Q148H, G140S] mutants
contain the fewest hydrogen bonds and van der Waals interactions with RAL as well as decreased
RAL-140s loop interactions. This suggests that decreased flexibility through changes in secondary
structure of the 140s loop caused by mutations at residues 140 and 148 disrupts RAL stabilizing
interactions (Table S1).
In the ELV complexes, there were no differences in the hydrogen bond network between
IN, viral DNA and ELV except for Q148R hydrogen bonding with ELV in the [Q148R] and
[Q148R, G140A] complexes (Fig. 7). The positively charged arginine side chain from the Q148R
mutation has been noted for its ability to disrupt ELV’s chelation mechanism via hydrogen
bonding with the ELV carboxyl group [95]. Our LigPlot analysis revealed hydrogen bonds
between the ELV carboxyl group and Q148R in the [Q148R] and [Q148R, G140A] mutants. The
hydrogen bond between ELV and Q148R is present in all of the frames selected for analysis
throughout the entire simulation in these mutants. This is further evidence for the role of Q148R
in ELV resistance.
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In the IN-DTG complexes, minor differences in the number of hydrogen bonds and van
der Waals interactions were observed between DTG, IN, and viral DNA in the mutant complexes
compared to the WT complex. As opposed to the RAL complexes, the mutations did not cause any
differences in DTG–140s loop interactions nor did they cause changes to the hydrogen bonding
network (Fig. 8). Non-covalent interactions between viral DNA and DTG, particularly hydrogen
bonds and van der Waals interactions, are decreased in the [Q148H, G140S] complex compared
to the WT (Table S2). [N155H, E92Q] also displays a decrease in van der Waals interactions with
viral DNA relative to the WT-DTG complex (Table S2).

57

Table 4-1: Raltegravir interactions with HIV- 1 IN, the 140s loop, and viral DNA.
Average raltegravirMutant
Average raltegravirAverage raltegravir
studied
protein interactions
140s loop interactions viral DNA (substrate)
interactions
H-bonds
vdW
Hvan der
H-bonds van der
interactions
bonds
Waals
Waals
interactions
interactions
WT

4.4±0.8

33.3±5.7

0.6±0.5

15±4.2

0.0

26.6±5.5

Q148H

4.1±1.4

42.3±5.7

0.4±0.5

15.9±5.3

0.1±0.3

16.8±7.7

Q148H,
G140S
Q148R

3.8±1.0

30.4± 6.5

0.3±0.5

8.7±6.0

0.2±0.4

20.7±11.8

3.5±0.8

30.2±9.3

0.2±0.4

10.2±7.0

0.0

11±6.1

Q148R,
G140A
N155H,
E92Q

3.5±1.4

25±7.0

0.8±0.6

6.5±5.5

0.2±0.4

38.6±10.1

4±0.8

32.4±7.8

0.8±0.4

16.6±6.7

1±0.5

15.6±6.0

Note: LigPlot+ and NucPlot were used to calculate hydrogen (H-bonds) and van der Waals
interactions between raltegravir, HIV-1 IN and viral DNA substrate. (Average +/- 1σ). The
changes in raltegravir interactions with HIV-1 IN is a result of HIV-1 IN structural
alterations.
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Figure 4-5: Hydrogen bonding interactions between HIV-1 IN and ELV (A) WT complex (B)
Q148R_G140A complex (C) Q148R complex. Residues involved in hydrogen bond with ELV are
shown in sphere representation to demonstrate their van der Waals volume.
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Figure 4-6: Hydrogen bonding interactions between HIV-1 IN and DTG (A) WT Complex (B)
N155H_E92Q Complex (C) Q148H_G140S Complex. Residues involved in hydrogen bond with
RAL are shown in sphere representation to demonstrate their van der Waals volume.
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Table 4-2: Dolutegravir interactions with HIV- 1 IN, the 140s loop, and viral DNA
Mutant
studied

WT
Q148H
Q148H,
G140S
Q148R
Q148R,
G140A
N155H,
E92Q

Average
dolutegravirprotein interactions

Average
dolutegravir 140s
loop interactions

Hbonds

van der
Waals
interactions
3.3±1.3 31.8±3.2
2.2±0.9 25.4±3.7
2.4±1.1 28.8±3.8

Hbonds

2.9±1.4 28.9±8.5
2.2±1.0 29.9±5.2

0.8±0.9 14.1±7.2
0.0
15±4.1

2.1±0.7 13.1±3.3
1.9±0.7 14.1±5.5

2.2±1.0 33.7±5.1

0.0

1.5±0.5 13.4±6.2

0.0
0.0
0.0

Average
dolutegravir- viral
DNA (substrate)
interactions
van der
Hvan der
Waals
bonds
Waals
interactions
interactions
13.4±6.8
1.5±0.7 16.4±4.7
9.4±2.8
0.9±0.3 22.9±4.9
17.6±3.5
0.1±0.3 10.6±3.8

18.8±5.7

Note: LigPlot+ and NucPlot were used to calculate hydrogen (H-bonds) and van der
Waals interactions between raltegravir, HIV-1 IN and viral DNA substrate. (Average +/1σ). The changes in dolutegravir interactions with HIV-1 IN is a result of HIV-1 IN
structural alterations.

61

4.3 DISCUSSION
In this study, the effect of HIV-1 IN mutations [Q148H], [Q148H, G140S], [Q148R],
[Q148R, G140A] and [N155H, E92Q] on INSTI-target interactions was investigated. Our results
suggest decreased flexibility of IN leads to a change in secondary structure and limited
conformational space. The mutations appear to affect IN both locally and globally while also
disrupting molecular recognition of RAL and ELV.
4.1 RESISTANCE MUTATIONS AFFECT HIV-1 IN CONFORMATION BOTH
LOCALLY AND GLOBALLY.
On a local scale, mutations affect the conformation of the 140s loop and active site, thereby
affecting IN and drug interactions. Conformational changes in the [Q148H/R, G140S/A] and
[N155H, E92Q] mutants appear to reduce interactions between RAL and the IN 140s loop and
viral DNA. Conformational changes in [Q148R] and [Q148R, G140A] caused residue 148 to
hydrogen bond with ELV’s carboxyl, disrupting its chelation mechanism which is essential for its
activity. Also, [Q148H, G140S], [Q148R], [Q148R, G140A] and [N155H, E92Q] all display
changes in the secondary structure of the 140s loop when in complex with ELV. These changes
may reflect reduced inhibitor–140s loop interactions resulting in lowered RAL and ELV potency.
In the DTG complexes, the mutants adopted a α-helix conformation in two residues in the 140s
loop relative to IN-ELV complexes (which had 4 residues adopt the α-helix conformation). Also,
DTG had similar interactions in the 140s loop when in complex with WT and mutant structures.
The mutations affect IN on a global scale as evidenced by the decreased RMSD over all three
functional domains compared to the un-complexed WT structure.
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4.2 VIRAL SUSCEPTIBILITY DATA (EC50) CORRELATES WITH DECREASED
FLEXIBILITY AND ALTERED INTERACTION NETWORKS IN SILICO
The results from our in silico experiments correlate with reported in vitro data presented in
Table 1. The double mutants ([Q148H, G140S], [Q148R, G140A], and [N155H, E92Q]) display
the largest EC50 fold change (FC) under RAL and ELV pressure. These mutants display transient
secondary structural changes by adopting a α-helical structure in the 140s loop during the 40 ns
simulation. Changes in the molecular recognition pattern of RAL are also seen, as indicated by the
loss of hydrogen bonds and van der Waals interactions with RAL. Furthermore, IN variants
containing the Q148R mutation displayed hydrogen bonds with the key ELV carboxyl group,
thereby causing mechanistic disruptions to the ELV chelation mechanism. In addition, interactions
between RAL and viral DNA decrease, which are required for ligand specificity and affinity.
Decreased flexibility of HIV-1 IN suggests changes in active site conformation may lead to
decreased drug binding/potency.
5. CONCLUSION
In conclusion, 40 ns MD simulations revealed mutant forms of IN displayed reduced
flexibility, alternative 140s loop secondary structure conformations, and altered molecular
recognition patterns compared to the wild-type enzyme. The results presented here with a full
length IN model in complex with INSTIs and viral DNA are consistent with our previous reports
using the CCD of IN in complex with RAL. Furthermore, the correlation between our results and
the reported in vitro data shows that this methodology can be a useful drug design and screening
tool. For example, in silico studies with new inhibitors should reveal similar flexibility patterns
between the wild type and a mutant target for optimal inhibitor potency.
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CHAPTER 5 : IN SILICO METHODOLOGY TO COMPARE HIV-1
IN STRAND TRANSFER INHIBITORS USING QIKPROP
Qikprop was used to predict the ADME/toxicity (administration, distribution, metabolism,
and excretion) parameters of the HIV-1 integrase strand transfer inhibitors raltegravir (RAL),
elvitegravir (ELV), dolutegravir (DTG), cabotegravir (CTV) and BI-224436 (BI-22). QikProp is
part of the Schrödinger small-molecule drug discovery suite and is used to predict ADME/toxicity
properties of preexisting and candidate drugs prior to synthesis and clinical trials for compound
modification (Schrödinger, 2013). QikProp also compares molecular properties to preexisting
approved drugs. This in silico approach saves time, resources and streamlines therapy. Based on
the ADME analysis, QikProp calculates stars (descriptor values), which evaluate the organic
properties of a drug based on Lipinski’s role of five, Jorgenson’s rule of three, and ADME factors.
Table 6.1 compares the chemical structure and QikProp star values for the first generation INIs
RAL and ELV to the second generation INIs DTG, CTV, and BI-22.
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Table 5-1: HIV-1 integrase inhibitor Qik Prop ADME stars ratings
HIV- 1 IN generic

HIV-1 IN inhibitor chemical structure

Qik Prop Stars

name
Raltegravir

0

Elvitegravir

0

Dolutegravir

0

Cabotegravir

1

BI- 224436

0
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RAL, ELV, DTG, CTV, and BI-2 MOL2 files were submitted to QikProp. QikProp
generated an output file that listed various ADME/toxicity parameters. The drug’s star value
reflects how its chemical properties lie within range of the typically approved drug.
All of the inhibitors had a stars score of 0-1 with CTV having the 1 star. CTV has one star
because it falls out of range (below) for the human serum albumin binding prediction which is a
distribution factor of the drugs pharmacology. However, most of the parameters for CTV are
similar to DTG's, indicating that they, theoretically, share an ADME profile. This qualifies CTV
as a second generation inhibitor.
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HIV-1 integrase (HIV-1 IN or IN) is a multimeric enzyme that integrates the HIV-1
genome into the chromosomes of infected CD4+ T-cells. Currently there are three FDA approved
HIV-1 IN strand transfer inhibitors (INSTIs) used in clinical practice: raltegravir (RAL),
elvitegravir (ELV), and dolutegravir (DTG). The [Q148H], [Q148H, G140S], [Q148R], [Q148R,
G140A] and [N155H, E92Q] mutations decrease IN susceptibility to RAL and ELV and may result
in therapeutic failure. As an indicator of protein flexibility, the root mean square deviation
(RMSD) of each HIV-1 IN residue in the last 5 ns of a 40 ns molecular dynamics simulation was
calculated for HIV-1 IN catalytic core domain as an apoprotein and in complex with RAL, ELV,
and DTG to study how the mutations affect HIV-1 IN flexibility. In addition, we studied the
relationship between HIV-1 IN flexibility and resistance. We found that the mutants reduced
overall HIV-1 IN flexibility relative to the WT IN apoprotein. We also observed that the catalytic
140s loop in the HIV-1 IN-INSTI complexes were more flexible in mutants that displayed higher
reported EC50 FC (fold change) values. To further investigate the mutations effect on the more
complexed full length HIV-1 IN structure, we used molecular dynamics simulations to study the
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impact of the mutants on binary (IN-viral DNA complex) and ternary (IN-viral DNA- INSTI) IN
flexibility. RMSD analyses revealed that that the mutants have a rigid structure relative to the WT
IN. Furthermore, mutant IN showed transient changes in the secondary structure of the 140s loop
compared to the WT. In addition to these reduced flexibility and structural changes, resistance
mutations alter the binding mode of RAL, ELV, and DTG to IN and viral DNA. This study is the
first to identify a structural basis of IN mechanism of resistance to INSTI’s resistance that develops
under treatment pressure in HIV-1 IN.
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